Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A2 | P43004 | 1/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
| ▸ | PRCP | P42785 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6913506 | 0.90 | SLC6A3 (0.37) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6914280 | 0.88 | SLC6A3 (0.43) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL9253196 | 0.82 | — | — | |
| SCHEMBL9611658 | 0.80 | PRCP (0.33) | SLC6A2SLC6A4SLC6A3PRCP | |
| SCHEMBL9287696 | 0.77 | — | — | |
| SCHEMBL18696407 | 0.77 | — | — | |
| SCHEMBL19034907 | 0.74 | DPP4 (0.30) | — | |
| SCHEMBL6914069 | 0.72 | CPN1 (0.40) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL9249651 | 0.72 | ALOX5 (0.37) | — | |
| SCHEMBL11962337 | 0.71 | SLC6A2 (0.42) | SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9688711-B2 | Antibacterial aminoglycoside analogs | ACHAOGEN, INC. (US) | 2017-06-27 | — | — | US | disclosed |
| US-8658606-B2 | Antibacterial aminoglycoside analogs | ACHAOGEN, INC. (US) | 2014-02-25 | — | — | US | disclosed |
| US-8653042-B2 | Antibacterial aminoglycoside analogs | ACHAOGEN, INC. (US) | 2014-02-18 | — | — | US | disclosed |
| US-8524675-B2 | Antibacterial aminoglycoside analogs | ACHAOGEN, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-8524689-B2 | Antibacterial aminoglycoside analogs | ACHAOGEN, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-8383596-B2 | Antibacterial aminoglycoside analogs | ACHAOGEN, INC. (US) | 2013-02-26 | — | — | US | disclosed |
| US-8372813-B2 | Antibacterial aminoglycoside analogs | ACHAOGEN, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-8367625-B2 | Antibacterial aminoglycoside analogs | ACHAOGEN, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20120283207-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2012-11-08 | — | — | US | disclosed |
| US-20120283207-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2012-11-08 | — | — | US | disclosed |
| WO-2010132759-A1 | ANTIBACTERIAL DERIVATIVES OF DIBEKACIN | ACHAOGEN, INC. (US) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010132760-A1 | ANTIBACTERIAL DERIVATIVES OF TOBRAMYCIN | ACHAOGEN, INC. (US) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010132839-A2 | AMINOGLYCOSIDE DOSING REGIMENS | ACHAOGEN, INC. (US) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010132777-A2 | TREATMENT OF URINARY TRACT INFECTIONS WITH ANTIBACTERIAL AMINOGLYCOSIDE COMPOUNDS | ACHAOGEN, INC. (US) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010132770-A1 | TREATMENT OF KLEBSIELLA PNEUMONIAE INFECTIONS WITH ANTIBACTERIAL AMINOGLYCOSIDE COMPOUNDS | ACHAOGEN, INC. (US) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010132765-A2 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2010-11-18 | — | — | WO | disclosed |
| US-20100099661-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2010-04-22 | — | — | US | disclosed |
| WO-2010042850-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2010-04-15 | — | — | WO | disclosed |
| WO-2010030704-A2 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2010-03-18 | — | — | WO | disclosed |
| WO-2009067692-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2009-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099661-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | MRPL21, MRPL9, NQO2 | SLC1A2 4020/4885SLC6A2 2482/4885SLC6A4 2493/4885 |
| US-20120283207-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | MRPL21, NQO2, QTRT1 | SLC1A2 3716/4885SLC6A2 3001/4885SLC6A4 3322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.